metoprolol has been researched along with Cardiac Arrest, Sudden in 39 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study." | 9.12 | Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure." | 9.12 | The safety of amiodarone in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, W; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "In a randomized double-blind design, 3029 patients with chronic congestive heart failure requiring diuretic therapy and with left ventricular dysfunction were randomized to treatment with carvedilol (n = 1511) or metoprolol tartrate (n = 1518) and titrated to target doses of 25 mg of carvedilol twice daily or 50 mg of metoprolol tartrate twice daily." | 9.11 | Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. ( Cleland, JG; Di Lenarda, A; Hanrath, P; Komajda, M; Lutiger, B; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Skene, A; Swedberg, K; Torp-Pedersen, C, 2005) |
| "A randomized trial was conducted to assess the efficacy of amiodarone versus metoprolol or no antiarrhythmic treatment to suppress asymptomatic ectopic activity and improve survival in patients who have had myocardial infarction with a left ventricular ejection fraction of 20 to 45% and > or = 3 ventricular premature complexes per hour (pairs or runs)." | 9.07 | Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death. ( Bayes de Luna, A; Cosin, J; Guindo, J; Marrugat, J; Navarro-López, F, 1993) |
| "To explore the effect of metoprolol tartrate tablets and recombinant human natriuretic peptide B (NPPB) on sudden cardiac death and malignant arrhythmias in patients with acute myocardial infarction and patients with heart failure (AMI-HF)." | 8.02 | Effect of metoprolol tartrate tablets and recombinant human B-type natriuretic peptide on the sudden cardiac death and malignant arrhythmias in patients with acute myocardial infarction and heart failure. ( Lin, Y; Liu, C; Yao, L; Zhang, L, 2021) |
| "This analysis was carried out to clarify the capacity of metoprolol to prevent cardiac events in Japanese post-myocardial infarction patients during a follow-up period of 16." | 7.70 | Retrospective analysis showing less cardiac events in post-myocardial infarction patients treated with metoprolol. Secondary Prevention Group. ( Hayashi, T; Inoki, T; Ishikawa, K; Kanamasa, K; Katayama, K; Kimura, A; Kitayama, K; Miyataka, M; Takenaka, T; Yabushita, H, 2000) |
| "This survival study was designed to address whether beta-1-blockade utilizing metoprolol CR/XL (controlled release/extended release) once daily added to standard therapy reduces mortality and morbidity in patients with decreased ejection fraction and symptoms of heart failure." | 6.19 | MERIT-HF mortality and morbidity data. ( Fagerberg, B; Hjalmarson, A, 2000) |
| "We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study." | 5.12 | Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure." | 5.12 | The safety of amiodarone in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, W; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "In a randomized double-blind design, 3029 patients with chronic congestive heart failure requiring diuretic therapy and with left ventricular dysfunction were randomized to treatment with carvedilol (n = 1511) or metoprolol tartrate (n = 1518) and titrated to target doses of 25 mg of carvedilol twice daily or 50 mg of metoprolol tartrate twice daily." | 5.11 | Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. ( Cleland, JG; Di Lenarda, A; Hanrath, P; Komajda, M; Lutiger, B; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Skene, A; Swedberg, K; Torp-Pedersen, C, 2005) |
| "A randomized trial was conducted to assess the efficacy of amiodarone versus metoprolol or no antiarrhythmic treatment to suppress asymptomatic ectopic activity and improve survival in patients who have had myocardial infarction with a left ventricular ejection fraction of 20 to 45% and > or = 3 ventricular premature complexes per hour (pairs or runs)." | 5.07 | Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death. ( Bayes de Luna, A; Cosin, J; Guindo, J; Marrugat, J; Navarro-López, F, 1993) |
| " In 1987, the Cardiac Arrest Study Hamburg (CASH), a prospective, randomized trial, was initiated to compare metoprolol, amiodarone, propafenone, and ICD implantation in patients surviving sudden cardiac death due to documented ventricular tachycardia and/or ventricular fibrillation." | 5.07 | Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators. ( Cappato, R; Kuck, KH; Rüppel, R; Schneider, MA; Siebels, J, 1993) |
| " Patients whose arrhythmia was inducible by programmed electrical stimulation were assigned to treatment with electrophysiologically guided drug therapy based on serial testing (61 patients) or with metoprolol (54 patients)." | 5.07 | A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. ( Andresen, D; Bach, P; Haberl, R; Hoffmann, E; Oeff, M; Steinbeck, G; von Leitner, ER, 1992) |
| "To explore the effect of metoprolol tartrate tablets and recombinant human natriuretic peptide B (NPPB) on sudden cardiac death and malignant arrhythmias in patients with acute myocardial infarction and patients with heart failure (AMI-HF)." | 4.02 | Effect of metoprolol tartrate tablets and recombinant human B-type natriuretic peptide on the sudden cardiac death and malignant arrhythmias in patients with acute myocardial infarction and heart failure. ( Lin, Y; Liu, C; Yao, L; Zhang, L, 2021) |
| "The effects of carvedilol and metoprolol succinate on appropriate and inappropriate implantable cardioverter defibrillator (ICD) therapy in patients with heart failure with reduced ejection fraction (HFrEF) are not fully understood." | 3.91 | A comparison of anti-arrhythmic efficacy of carvedilol vs metoprolol succinate in patients with implantable cardioverter-defibrillators. ( Alqam, B; Ayan, M; Cross, M; Gheith, Z; Habash, F; Paydak, H; Vallurupalli, S, 2019) |
| "Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4." | 3.72 | [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004) |
| "This analysis was carried out to clarify the capacity of metoprolol to prevent cardiac events in Japanese post-myocardial infarction patients during a follow-up period of 16." | 3.70 | Retrospective analysis showing less cardiac events in post-myocardial infarction patients treated with metoprolol. Secondary Prevention Group. ( Hayashi, T; Inoki, T; Ishikawa, K; Kanamasa, K; Katayama, K; Kimura, A; Kitayama, K; Miyataka, M; Takenaka, T; Yabushita, H, 2000) |
| "In patients prone to sudden cardiac death, there is a reduction in TWA amplitude following the administration of antiadrenergic drugs." | 2.70 | Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study. ( Grönefeld, G; Hohnloser, SH; Klingenheben, T; Li, YG, 2001) |
| "In 1987, the Cardiac Arrest Study Hamburg (CASH), a prospective, multicenter, randomized controlled study, was started in survivors of sudden cardiac death resulting from documented ventricular tachyarrhythmias." | 2.67 | Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). ( Kuck, KH; Siebels, J, 1994) |
| "A novel familial arrhythmia syndrome, cardiac ryanodine receptor (RyR2) calcium release deficiency syndrome (CRDS), has recently been described." | 1.72 | Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome. ( Chen, SRW; Dreau, HMP; Ginks, MR; Guo, W; Li, Y; McGuire, K; Ormerod, JOM; Ormondroyd, E; Rajappan, K; Sarton, CNS; Taylor, J; Taylor, JC; Wang, R; Watkins, H; Wei, J, 2022) |
| "Carvedilol treatment was a strong predictor for being on target dose of BB at time of implant, as was treatment with angiotensin-converting enzyme inhibitors and/or spironolactone, no history of myocardial infarction, younger age and less pronounced heart failure symptoms." | 1.48 | The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: insight from Danish nationwide registers. ( Gislason, GH; Johansen, JB; Jøns, C; Nielsen, JC; Petersen, HH; Riahi, S; Ruwald, AC; Torp-Pedersen, C; Vinther, M, 2018) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare but potentially lethal inherited arrhythmia syndrome induced by adrenergic stress." | 1.48 | A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child. ( Duan, H; Hua, Y; Li, Y; Lu, Y; Qiao, L; Wang, C; Yan, S; Zhou, K, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (30.77) | 18.2507 |
| 2000's | 17 (43.59) | 29.6817 |
| 2010's | 6 (15.38) | 24.3611 |
| 2020's | 4 (10.26) | 2.80 |
| Authors | Studies |
|---|---|
| Ormerod, JOM | 1 |
| Ormondroyd, E | 1 |
| Li, Y | 2 |
| Taylor, J | 1 |
| Wei, J | 1 |
| Guo, W | 1 |
| Wang, R | 1 |
| Sarton, CNS | 1 |
| McGuire, K | 1 |
| Dreau, HMP | 1 |
| Taylor, JC | 1 |
| Ginks, MR | 1 |
| Rajappan, K | 1 |
| Chen, SRW | 1 |
| Watkins, H | 1 |
| Liu, C | 1 |
| Yao, L | 1 |
| Zhang, L | 1 |
| Lin, Y | 1 |
| Atici, A | 1 |
| Asoğlu, R | 1 |
| Barman, HA | 1 |
| Sahin, I | 1 |
| Zhang, JG | 1 |
| Dai, SP | 1 |
| Liu, H | 1 |
| Xu, ZS | 1 |
| Ruwald, AC | 2 |
| Gislason, GH | 2 |
| Vinther, M | 2 |
| Johansen, JB | 2 |
| Nielsen, JC | 2 |
| Petersen, HH | 1 |
| Torp-Pedersen, C | 5 |
| Riahi, S | 2 |
| Jøns, C | 2 |
| Duan, H | 1 |
| Lu, Y | 1 |
| Yan, S | 1 |
| Qiao, L | 1 |
| Hua, Y | 1 |
| Zhou, K | 1 |
| Wang, C | 1 |
| Philbert, BT | 1 |
| Ayan, M | 1 |
| Habash, F | 1 |
| Alqam, B | 1 |
| Gheith, Z | 1 |
| Cross, M | 1 |
| Vallurupalli, S | 1 |
| Paydak, H | 1 |
| Abu-Zeitone, A | 1 |
| Peterson, DR | 1 |
| Polonsky, B | 1 |
| McNitt, S | 1 |
| Moss, AJ | 1 |
| McMurray, JJ | 1 |
| Sinagra, G | 1 |
| Perkan, A | 1 |
| Cherubini, A | 1 |
| Salvatore, L | 1 |
| Di Lenarda, A | 4 |
| Coca, SG | 1 |
| Buller, GK | 1 |
| Kanopskiĭ, SG | 1 |
| Staritskiĭ, AG | 1 |
| Bozhko, AA | 1 |
| Prendergast, HM | 1 |
| Soorya, N | 1 |
| Erickson, T | 1 |
| Poole-Wilson, PA | 3 |
| Swedberg, K | 3 |
| Cleland, JG | 3 |
| Hanrath, P | 1 |
| Komajda, M | 3 |
| Lutiger, B | 1 |
| Metra, M | 3 |
| Remme, WJ | 2 |
| Scherhag, A | 3 |
| Skene, A | 1 |
| Hjemdahl, P | 2 |
| Eriksson, SV | 1 |
| Held, C | 2 |
| Forslund, L | 2 |
| Näsman, P | 1 |
| Rehnqvist, N | 2 |
| Reiffel, JA | 1 |
| Kowey, PR | 1 |
| Binder, WD | 1 |
| Fifer, MA | 1 |
| King, ME | 1 |
| Stone, JR | 1 |
| Nakashidze, NM | 1 |
| Machavariani, PT | 1 |
| Spark, P | 2 |
| Moullet, C | 2 |
| Lukas, MA | 2 |
| Remme, W | 1 |
| Navarro-López, F | 1 |
| Cosin, J | 1 |
| Marrugat, J | 1 |
| Guindo, J | 1 |
| Bayes de Luna, A | 1 |
| Siebels, J | 4 |
| Cappato, R | 2 |
| Rüppel, R | 2 |
| Schneider, MA | 2 |
| Kuck, KH | 4 |
| Viskin, S | 1 |
| Belhassen, B | 1 |
| Raza, A | 1 |
| Lurje, L | 1 |
| Wennerblom, B | 1 |
| Tygesen, H | 1 |
| Karlsson, T | 1 |
| Hjalmarson, A | 2 |
| Kulbertus, H | 1 |
| Fesmire, SI | 1 |
| Marcoux, LG | 1 |
| Lyyski, DS | 1 |
| Sprague, MK | 1 |
| Kennedy, HL | 1 |
| Eichhorn, EJ | 1 |
| Fagerberg, B | 2 |
| Ishikawa, K | 1 |
| Miyataka, M | 1 |
| Kanamasa, K | 1 |
| Hayashi, T | 1 |
| Takenaka, T | 1 |
| Inoki, T | 1 |
| Katayama, K | 1 |
| Kimura, A | 1 |
| Yabushita, H | 1 |
| Kitayama, K | 1 |
| Kovach, JA | 1 |
| Nearing, BD | 1 |
| Verrier, RL | 1 |
| Klingenheben, T | 1 |
| Grönefeld, G | 1 |
| Li, YG | 1 |
| Hohnloser, SH | 1 |
| Björkander, I | 1 |
| Ericson, M | 1 |
| Kahan, T | 1 |
| Steinbeck, G | 1 |
| Andresen, D | 1 |
| Bach, P | 1 |
| Haberl, R | 1 |
| Oeff, M | 1 |
| Hoffmann, E | 1 |
| von Leitner, ER | 1 |
| Herms, J | 1 |
| Schneider, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
5 reviews available for metoprolol and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
[Treatment of heart failure: an update].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor | 2002 |
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 2; Anti-Arrhythmia Agents; Carbazoles; Ca | 2005 |
A review of carvedilol arrhythmia data in clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca | 2005 |
The merit of beta(1)-blockade in heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Death, Sudden, Cardiac; Heart F | 1999 |
MERIT-HF mortality and morbidity data.
Topics: Adrenergic beta-Antagonists; Death, Sudden, Cardiac; Delayed-Action Preparations; Heart Failure; Hos | 2000 |
17 trials available for metoprolol and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Double-Blind Method; Fe | 2005 |
Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS).
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Death, Sudden, Cardiac; Diab | 2006 |
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 2; Anti-Arrhythmia Agents; Carbazoles; Ca | 2005 |
[Estimation of effectiveness of the prevention of sudden cardiac death in patients with myocardial infarction].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Female; Humans; Male; M | 2006 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
The safety of amiodarone in patients with heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; | 2007 |
Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death.
Topics: Aged; Amiodarone; Cardiac Complexes, Premature; Death, Sudden, Cardiac; Female; Humans; Male; Metopr | 1993 |
ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1993 |
Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg).
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Female; Hea | 1994 |
Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1993 |
Heart rate variability after acute myocardial infarction in patients treated with atenolol and metoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Autonomic Nervous System; Cross-Over Studies; De | 1997 |
[Clinical study of the month. The MERIT-HF study].
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Di | 1999 |
MERIT-HF mortality and morbidity data.
Topics: Adrenergic beta-Antagonists; Death, Sudden, Cardiac; Delayed-Action Preparations; Heart Failure; Hos | 2000 |
Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Cause of Death; Coronary Disease; Death, | 2001 |
Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Biomarkers; | 2002 |
A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; E | 1992 |
[Prospective long-term ECG study of 100 patients surviving sudden cardiac death].
Topics: Adult; Aged; Amiodarone; Death, Sudden, Cardiac; Defibrillators, Implantable; Electrocardiography, A | 1992 |
19 other studies available for metoprolol and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Channelopathies; Death, Sudden, Cardiac; Flecainide; Humans; | 2022 |
Effect of metoprolol tartrate tablets and recombinant human B-type natriuretic peptide on the sudden cardiac death and malignant arrhythmias in patients with acute myocardial infarction and heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biomarke | 2021 |
The importance of the epinephrine provocation test for the hidden type-1 congenital long QT syndrome.
Topics: Adolescent; Death, Sudden, Cardiac; DNA; Electrocardiography; Epinephrine; Female; Heterozygote; Hum | 2020 |
Comparison of carvedilol versus metoprolol in patients with acute myocardial infarction: A protocol for systematic review and meta-analysis.
Topics: Arrhythmias, Cardiac; Carvedilol; Death, Sudden, Cardiac; Humans; Meta-Analysis as Topic; Metoprolol | 2021 |
The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: insight from Danish nationwide registers.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Defibrillators, I | 2018 |
A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
Topics: Amiodarone; Anti-Arrhythmia Agents; Child; Death, Sudden, Cardiac; Delayed Diagnosis; Electrocardiog | 2018 |
Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Death, Sudden, Cardiac; Defibrillators, Implantable; | 2018 |
A comparison of anti-arrhythmic efficacy of carvedilol vs metoprolol succinate in patients with implantable cardioverter-defibrillators.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arkansas; Carvedilol; Cause of Death; Death, Su | 2019 |
Efficacy of different beta-blockers in the treatment of long QT syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Atenolol; Child; Child, Preschool; Death, Sudden, Ca | 2014 |
Heart failure: acute ischemic events in HF--should we include sudden death?
Topics: Adrenergic beta-1 Receptor Antagonists; Antihypertensive Agents; Benzopyrans; Death, Sudden, Cardiac | 2011 |
COMET: a proposed mechanism of action to explain the results and concerns about dose.
Topics: Adenosine Triphosphatases; Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol | 2003 |
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
Sudden death after IV metoprolol administration in a patient with cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Alcoholism; Cardiomyopathy, Dilated; Death, Sudden, Cardiac; Ele | 2004 |
Case records of the Massachusetts General Hospital. Case 26-2005. A 48-year-old man with sudden loss of consciousness while jogging.
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Diagnosis, Differentia | 2005 |
Clinical problem-solving. When you only live twice.
Topics: Adult; Death, Sudden, Cardiac; Defibrillators, Implantable; Diagnosis, Differential; Exercise Test; | 1995 |
Beta-receptor blockade in preventing sudden death.
Topics: Adrenergic beta-Antagonists; Atenolol; Death, Sudden, Cardiac; Humans; Metoprolol; Practolol; Sotalo | 1993 |
Effect of selective versus nonselective beta blockade on QT dispersion in patients with nonischemic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Death, Su | 1999 |
Retrospective analysis showing less cardiac events in post-myocardial infarction patients treated with metoprolol. Secondary Prevention Group.
Topics: Adrenergic beta-Antagonists; Aged; Death, Sudden, Cardiac; Drug Evaluation; Female; Heart Failure; H | 2000 |
Angerlike behavioral state potentiates myocardial ischemia-induced T-wave alternans in canines.
Topics: Adrenergic beta-Antagonists; Anger; Animals; Arousal; Blood Pressure; Death, Sudden, Cardiac; Diseas | 2001 |